World Health Organization site
Skip Navigation Links

Main
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register.
Register: ClinicalTrials.gov
Last refreshed on: 12 December 2020
Main ID:  NCT01132482
Date of registration: 16/04/2010
Prospective Registration: Yes
Primary sponsor: National Jewish Health
Public title: Effects of Sildenafil on CFTR-dependent Ion Transport Activity
Scientific title: Phase II Study of the Effects of Sildenafil on CFTR-dependent Ion Transport Activity
Date of first enrolment: October 2015
Target sample size: 19
Recruitment status: Completed
URL:  https://clinicaltrials.gov/show/NCT01132482
Study type:  Interventional
Study design:  Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).  
Phase:  Phase 2
Countries of recruitment
United States
Contacts
Name:     Jennifer L Taylor-Cousar, MD
Address: 
Telephone:
Email:
Affiliation:  National Jewish Health
Key inclusion & exclusion criteria

Inclusion Criteria:

1. Confirmed diagnosis of CF based on the following criteria: Positive sweat chloride
=60mEq/liter (by pilocarpine iontophoresis) and genotype with two F508del CFTR
mutations, and accompanied by one or more clinical features consistent with the CF
phenotype

2. Male or female subjects = 18 years of age

3. FEV1 = 50% predicted (Hankinson)

4. Clinically stable without evidence of acute upper or lower respiratory tract infection
or current pulmonary exacerbation within the 14 days prior to the screening visit

5. Ability to reproducibly perform spirometry (according to ATS criteria)

6. Ability to understand and sign a written informed consent or assent and comply with
the requirements of the study

7. Willing and able to perform nasal potential difference testing

8. No changes in use of nasal medications within 2 weeks of screening visit

9. If on Orkambi, has been on stable Orkambi dose for at least 4 weeks at day 1.

Exclusion Criteria:

1. History of hypersensitivity to sildenafil

2. Use of an investigational agent within the 4-week period prior to Visit 1 (Day 0)

3. Breastfeeding, pregnant, or verbal expression of unwillingness to practice an
acceptable birth control method (abstinence, hormonal or barrier methods, partner
sterilization or intrauterine device) during participation in the study

4. History of significant hepatic (SGOT or SGPT > 3 times the upper limit of normal at
screening, documented biliary cirrhosis, or portal hypertension), cardiovascular
(history of aortic stenosis, coronary artery disease, pulmonary hypertension with
right ventricular systolic pressure >55 mmHg or life-threatening arrhythmia),
neurological (history of stroke), hematologic (history of bleeding diathesis),
ophthalmologic (history of retinal impairment or non-arteritic ischemic optic
neuritis) or renal impairment (creatinine >1.8 mg/dL.)

5. Inability to swallow pills

6. Previous lung transplantation

7. Use of concomitant nitrates, a-blocker, or Ca channel blocker

8. Use of concomitant medications known to be potent inhibitors of CYP3A4 (e.g.
ketoconazole, itraconazole, ritonavir, clarithromycin, erythromycin, rifampin,
verapamil)

9. Presence of a condition or abnormality that in the opinion of the investigator would
compromise the safety of the subject or the quality of the data

10. Weight less than 40 kg

11. History of sputum or throat swab culture yielding Burkholderia cepacia within 2 years
of screening

12. History of nasal disease or nasal surgery that would, in the opinion of the
investigator, impede accurate measurements of NPD

13. Use of anticoagulant medication (e.g. heparin, coumadin)

14. Resting room air oxygen saturation <93%

15. Use of nighttime oxygen

15) History of migraine headaches 16) Baseline BP of < 90/50 mm Hg



Age minimum: 18 Years
Age maximum: N/A
Gender: All
Health Condition(s) or Problem(s) studied
Cystic Fibrosis
Intervention(s)
Drug: Placebo
Drug: Sildenafil
Primary Outcome(s)
Change in Sodium Conductance by Nasal Potential Difference (NPD) [Time Frame: Baseline and day 28]
Secondary Outcome(s)
Change in CF Heath Related Quality of Life Questionnaire (CFQ-R) [Time Frame: Baseline and day 28]
Change in Chloride Conductance by NPD [Time Frame: Baseline and day 28]
Change in Lung Clearance Index [Time Frame: Baseline and day 28]
Change in Pulmonary Function by Spirometry [Time Frame: Baseline and day 28]
Change in Serum Sildenafil Pharmacokinetics [Time Frame: Baseline and day 28]
Change in Sweat Chloride Concentration by Pilocarpine Iontophoresis [Time Frame: Baseline and day 28]
Secondary ID(s)
Sildenafil CFTR
Source(s) of Monetary Support
Please refer to primary and secondary sponsors
Secondary Sponsor(s)
Ethics review
Results
Results available: Yes
Date Posted: 26/02/2019
Date Completed:
URL: https://clinicaltrials.gov/ct2/show/results/NCT01132482
Disclaimer: Trials posted on this search portal are not endorsed by WHO, but are provided as a service to our users. In no event shall the World Health Organization be liable for any damages arising from the use of the information linked to in this section. None of the information obtained through use of the search portal should in any way be used in clinical care without consulting a physician or licensed health professional. WHO is not responsible for the accuracy, completeness and/or use made of the content displayed for any trial record.
Copyright - World Health Organization - Version 3.6 - Version history